STAB THERAPEUTICS
- Biotech or pharma, therapeutic R&D
STAb Tx is an early-stage biotech spin-off developing a next-generation immune redirection cell therapy, STAb-T therapies, to re-arm the patient’s immune system. Our novel STAb-T cells produce and secrete bispecific T cell engagers (TCE), targeting solid and blood tumors with potent and sustained responses.
STAb-T cells function as “fully human factories,” continuously producing TCEs in vivo to mobilize the entire T-cell repertoire in search and destruction of tumors, even in low antigen conditions. STAb-T therapy uniquely combines the strengths of CAR-T and TCEs, to achieve benefits that neither approach can accomplish alone. Our approach is grounded in amplifying the serial triggering and killing effect of activated T cells, while also recruiting and physiologically activating bystander T cells through the sustained in vivo secretion of TCEs. Additionally, STAb-T cells create a reservoir of memory STAb-T cells to prevent tumor relapse, promoting long-term immunity.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}